Table 4.
Tumor response for sorafenib treatment
| Variable, n (%) | All (N = 2109) | eGFR (mL/min/1.73 m2) | p-value* | p-value† | |
|---|---|---|---|---|---|
| < 60 (n = 1053) | ≥ 60 (n = 1056) | ||||
| Complete response | 28 (1.3) | 15 (1.4) | 13 (1.2) | 0.6980 | 0.2759 |
| Partial response | 370 (17.5) | 181 (17.2) | 189 (17.9) | 0.6687 | |
| Stable disease | 1015 (48.1) | 517 (49.1) | 498 (47.2) | 0.3729 | |
| Progressive disease | 465 (22.1) | 212 (20.1) | 253 (24.0) | 0.0341 | |
| Non-evaluable | 231 (11.0) | 128 (12.2) | 103 (9.8) | 0.0774 | |
| Overall response rate (ORR) | 398 (18.9) | 196 (18.6) | 202 (19.1) | 0.7623 | |
| Disease control rate (DCR) | 1413 (67.0) | 713 (67.7) | 700 (66.3) | 0.4870 | |
*2 × 2 Pearson χ2 tests for each type of response
†Pearson χ2 test for overall independence (excludes non-evaluable data)